Organigram Global Inc. brought in $42.5 million in net income for the three months ending March 31, 2025 (Q2 2025) from $102.8 million in gross revenue and $65.6 million in net revenue.
Net income for the Moncton-based producer increased 163.8% year-over-year compared to Q2 2024’s net loss of $27.1 million and an increase from the $23 million net loss in Q1 2025.
The company harvested 21,133 kilograms of cannabis flower in the first three months of 2025 and sold 19,701 kilograms, a 1% and 17% increase YOY, respectively. Organigram attributed this increase to the success of its large format value products, an increase in international sales, and higher sales of infused pre-rolls.
Of the $65.6 million in net revenue, $56.7 million (87%) was from sales in the adult-use market in Canada, while $6.1 million (9%) was sold in the international market, and $2.9 million (4%) was from other revenues.
These increases in recreational cannabis revenue were mainly attributed to financial contributions from Motif and international sales, respectively. Organigram acquired Motif in December 2025. The newly acquired Motif London Facility, which serves as a dedicated central Ontario distribution hub, is anticipated to reduce shipping costs and streamline logistics, enhancing overall operational efficiency.
In addition to its flagship Moncton facility, Organigram has acquired production facilities across Canada, including in Ontario, Quebec, and Manitoba.
“Our record revenue this quarter reflects the strength of our brands and our ability to execute across both domestic and international markets,” said Beena Goldenberg, Organigram’s CEO. “We are unlocking meaningful global growth potential—from increasing sales into key international markets like Germany, to our entrance into the US hemp-derived beverage space. We expect this momentum to continue as we further strengthen our leadership in Canada and head into the seasonally stronger back half of the year.”
While dried flower and pre-rolls continue to dominate Organigram’s sales, in Q2 Fiscal 2025, the company held the number three market position in the gummy category and holds 5.6% of the cannabis infused beverage category. Through the company’s acquisition of Motif, Organigram also leads in market share in the vape category.
Organigram also sells internationally with medical customers in Australia, Germany, and the UK, and has completed a significant strategic investment in a German cannabis leader, Sanity Group, to establish a foothold in the growing European cannabis market.
The company has also completed strategic investments into two U.S.-based companies, OBX and Phylos. Through its acquisition of CPL, Organigram participates in the hemp-derived beverages segment. The company says it continues to monitor and explore opportunities in the US market.
In February 2025, Organigram also closed on the final $41.5 million tranche of funding from British American Tobacco’s Jupiter Pool funds, helping strengthen the company’s balance sheet and fuel international expansion goals.
In 2023, Organigram said most of a $124.6 million investment from British American Tobacco (BAT) would be used to create a strategic investment pool named Jupiter, focusing on emerging cannabis opportunities, including geographic expansion. In 2021, the deal was first announced as a C$221 million strategic investment and has continued to evolve over the years.
The company paid nearly $37.2 million in excise taxes on its gross revenue of $102.8 million, for a rate of about 36%.
Written May 12, 2025 | Sarah Clark Posted in Stratcann